These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 31624127)

  • 1. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
    Zammataro L; Lopez S; Bellone S; Pettinella F; Bonazzoli E; Perrone E; Zhao S; Menderes G; Altwerger G; Han C; Zeybek B; Bianchi A; Manzano A; Manara P; Cocco E; Buza N; Hui P; Wong S; Ravaggi A; Bignotti E; Romani C; Todeschini P; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Angioli R; Raspagliesi F; Scambia G; Choi J; Dong W; Bilguvar K; Alexandrov LB; Silasi DA; Huang GS; Ratner E; Azodi M; Schwartz PE; Pirazzoli V; Stiegler AL; Boggon TJ; Lifton RP; Schlessinger J; Santin AD
    Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22730-22736. PubMed ID: 31624127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.
    Bellone S; Jeong K; Halle MK; Krakstad C; McNamara B; Greenman M; Mutlu L; Demirkiran C; Hartwich TMP; Yang-Hartwich Y; Zipponi M; Buza N; Hui P; Raspagliesi F; Lopez S; Paolini B; Milione M; Perrone E; Scambia G; Altwerger G; Ravaggi A; Bignotti E; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Quick CM; Angioli R; Terranova C; Zaidi S; Nandi S; Alexandrov LB; Siegel ER; Choi J; Schlessinger J; Santin AD
    Proc Natl Acad Sci U S A; 2024 Apr; 121(17):e2321898121. PubMed ID: 38625939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
    Bonazzoli E; Cocco E; Lopez S; Bellone S; Zammataro L; Bianchi A; Manzano A; Yadav G; Manara P; Perrone E; Haines K; Espinal M; Dugan K; Menderes G; Altwerger G; Han C; Zeybek B; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2019 Apr; 153(1):158-164. PubMed ID: 30630630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.
    Lopez S; Cocco E; Black J; Bellone S; Bonazzoli E; Predolini F; Ferrari F; Schwab CL; English DP; Ratner E; Silasi DA; Azodi M; Schwartz PE; Terranova C; Angioli R; Santin AD
    Mol Cancer Ther; 2015 Nov; 14(11):2519-26. PubMed ID: 26333383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERBB2 mutation: A promising target in non-squamous cervical cancer.
    Xiang L; Jiang W; Ye S; He T; Pei X; Li J; Chan DW; Ngan HYS; Li F; Tao P; Shen X; Zhou X; Wu X; Yang G; Yang H
    Gynecol Oncol; 2018 Feb; 148(2):311-316. PubMed ID: 29279289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer.
    Martell K; McIntyre JB; Kornaga EN; Chan AMY; Phan T; Köbel M; Enwere EK; Dean ML; Ghatage P; Lees-Miller SP; Doll CM
    Gynecol Oncol; 2020 Sep; 158(3):776-784. PubMed ID: 32653099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic analysis of cervical carcinoma identifies Alpelisib as a therapeutic option for PIK3CA-mutant cervical carcinoma via the PI3K/AKT pathway.
    Wei Y; Lin S; Zhi W; Chu T; Liu B; Peng T; Xu M; Ding W; Cao C; Wu P
    J Med Virol; 2023 Mar; 95(3):e28656. PubMed ID: 36905114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway.
    Lou H; Villagran G; Boland JF; Im KM; Polo S; Zhou W; Odey U; Juárez-Torres E; Medina-Martínez I; Roman-Basaure E; Mitchell J; Roberson D; Sawitzke J; Garland L; Rodríguez-Herrera M; Wells D; Troyer J; Pinto FC; Bass S; Zhang X; Castillo M; Gold B; Morales H; Yeager M; Berumen J; Alvirez E; Gharzouzi E; Dean M
    Clin Cancer Res; 2015 Dec; 21(23):5360-70. PubMed ID: 26080840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative genomics of high grade neuroendocrine carcinoma of the cervix.
    Hillman RT; Cardnell R; Fujimoto J; Lee WC; Zhang J; Byers LA; Ramalingam P; Leitao M; Swisher E; Futreal PA; Frumovitz M
    PLoS One; 2020; 15(6):e0234505. PubMed ID: 32544169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
    Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
    Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway.
    Adam L; San Lucas FA; Fowler R; Yu Y; Wu W; Liu Y; Wang H; Menter D; Tetzlaff MT; Ensor J; Manyam G; Arold ST; Huff C; Kopetz S; Scheet P; Overman MJ
    Clin Cancer Res; 2019 Jan; 25(2):641-651. PubMed ID: 30352910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
    English DP; Bellone S; Cocco E; Bortolomai I; Pecorelli S; Lopez S; Silasi DA; Schwartz PE; Rutherford T; Santin AD
    Am J Obstet Gynecol; 2013 Nov; 209(5):465.e1-9. PubMed ID: 23891627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
    Janku F; Wheler JJ; Westin SN; Moulder SL; Naing A; Tsimberidou AM; Fu S; Falchook GS; Hong DS; Garrido-Laguna I; Luthra R; Lee JJ; Lu KH; Kurzrock R
    J Clin Oncol; 2012 Mar; 30(8):777-82. PubMed ID: 22271473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
    Lopez S; Schwab CL; Cocco E; Bellone S; Bonazzoli E; English DP; Schwartz PE; Rutherford T; Angioli R; Santin AD
    Gynecol Oncol; 2014 Nov; 135(2):312-7. PubMed ID: 25172762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
    Kim SI; Lee JW; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Seo JS
    Gynecol Oncol; 2018 Feb; 148(2):375-382. PubMed ID: 29233531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Landscape of genomic alterations in cervical carcinomas.
    Ojesina AI; Lichtenstein L; Freeman SS; Pedamallu CS; Imaz-Rosshandler I; Pugh TJ; Cherniack AD; Ambrogio L; Cibulskis K; Bertelsen B; Romero-Cordoba S; Treviño V; Vazquez-Santillan K; Guadarrama AS; Wright AA; Rosenberg MW; Duke F; Kaplan B; Wang R; Nickerson E; Walline HM; Lawrence MS; Stewart C; Carter SL; McKenna A; Rodriguez-Sanchez IP; Espinosa-Castilla M; Woie K; Bjorge L; Wik E; Halle MK; Hoivik EA; Krakstad C; Gabiño NB; Gómez-Macías GS; Valdez-Chapa LD; Garza-Rodríguez ML; Maytorena G; Vazquez J; Rodea C; Cravioto A; Cortes ML; Greulich H; Crum CP; Neuberg DS; Hidalgo-Miranda A; Escareno CR; Akslen LA; Carey TE; Vintermyr OK; Gabriel SB; Barrera-Saldaña HA; Melendez-Zajgla J; Getz G; Salvesen HB; Meyerson M
    Nature; 2014 Feb; 506(7488):371-5. PubMed ID: 24390348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
    Merino VF; Cho S; Liang X; Park S; Jin K; Chen Q; Pan D; Zahnow CA; Rein AR; Sukumar S
    Mol Oncol; 2017 May; 11(5):552-566. PubMed ID: 28296140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
    Chia SKL; Martin M; Holmes FA; Ejlertsen B; Delaloge S; Moy B; Iwata H; von Minckwitz G; Mansi J; Barrios CH; Gnant M; Tomašević Z; Denduluri N; Šeparović R; Kim SB; Jakobsen EH; Harvey V; Robert N; Smith J; Harker G; Zhang B; Eli LD; Ye Y; Lalani AS; Buyse M; Chan A
    Breast Cancer Res; 2019 Mar; 21(1):39. PubMed ID: 30867034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation.
    Hernandez SF; Chisholm S; Borger D; Foster R; Rueda BR; Growdon WB
    Gynecol Oncol; 2016 Jun; 141(3):570-579. PubMed ID: 27017985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the β-catenin/SIRT3 signaling pathway in cervical cancer.
    Jiang W; He T; Liu S; Zheng Y; Xiang L; Pei X; Wang Z; Yang H
    J Hematol Oncol; 2018 Dec; 11(1):139. PubMed ID: 30547809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.